Gyros Partners with EMD Millipore to Develop and Commercialize Immunoassays on Gyrolab Platform | GenomeWeb

Gyros this week announced a partnership with EMD Millipore to develop, manufacture, and commercialize immunoassay kits for the Gyrolab platform.

The new kits will take advantage of the capabilities of Gyros' microfluidic technology, which, according to the company, requires smaller sample and reagent volumes and offers increased dynamic range and reduced cross-talk and matrix interference compared to traditional ELISAs.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

Genetic analysis confirms that blood found on leaves collected near Marche-les-Dames some 80 years ago belongs to King Albert I of Belgium.

Researchers in the US begin to seek participants for the 1 million-person precision medicine cohort, the New York Times reports.

A new report indicates that women are underrepresented among US patent holders.

In PLOS this week: cell-free DNA from tumors is shorter than DNA from healthy cells, type 2 diabetes-related loci, and more.